NOVI, Mich.– Delphinus Medical Technologies, a pioneering medical imaging company that developed the SoftVue™ Breast Tomographic Ultrasound, announced today that Michael Emery has joined the company as chief financial officer (CFO). Emery has over 30 years of experience in financial executive leadership in the pharmaceutical and medical device industries.
“Michael’s strong resume of strategic planning, financial management and building high-performance teams, makes him the ideal leader to help us execute our financial plan here at Delphinus,” said Delphinus CEO Scott White. “We are in an exciting time for our organization, where the potential for growth and long-term goal achievement is paramount and requires a financial leader who can position us for success.”
As CFO and COO at Tyber Medical, Emery aligned the company for investment and financial success, streamlined business processes, drove cost reductions and improved efficiencies. Before his role at Tyber, he led financial executive teams at Plasma Surgical and Abbott Pharmaceuticals. His position at Abbott spanned over a decade, where he began at Solvay Pharmaceuticals and carried out multiple financial initiatives, including aligning Solvay for purchase and integrating business operations from Solvay into Abbott. Most recently before joining Delphinus, Emery consulted for multiple companies in the healthcare and medical device space to help strategize and position companies to meet and exceed short and long-term financial goals.
“It is an honor to join a company that is experiencing immense growth as it enters into commercial stage,” said Emery. “The SoftVue system addresses a large gap in the U.S. healthcare system for women with dense breast tissue, and I look forward to supporting Delphinus’s expansion in the healthcare market and enabling the company to achieve all of its current and future business goals.”
Delphinus Medical Technologies developed SoftVue, an FDA-approved whole breast ultrasound tomography system, to screen women with dense breasts in addition to mammography. Women with dense breasts, which make up 40 percent of women in the U.S., have an increased risk of developing breast cancer and the cancer going undetected using mammography alone. When paired with the standard screening method, SoftVue has been shown to identify up to 20 percent more cancers, while also reducing false positives and decreasing unnecessary call-backs and biopsies.
